Tag - TRVI

SVB Securities initiated coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $6 price target. The stock closed at $1.99 on Nov. 21. TRVI is a clinical-stage biopharmaceutical company developing...